Christopher G. Morris
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christopher G. Morris has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Amy M. Crisp
Center for Data Solutions, University of Florida College of Medicine Jacksonville, Jacksonville, FL
2 shared publications - William M. Mendenhall
Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL 32610, USA
2 shared publications Aaron J. Katz
Department of Population Health, University of Kansas Medical Center, Kanas City, KS
1 shared publicationAdeel Markatia
Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, Florida
1 shared publication- Alexander Scott Parker
College of Medicine, University of Florida, Jacksonville, FL 32209, USA
1 shared publication - Camille Ragin
Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
1 shared publication
Latest Publications
- 29 July 2026
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 126 (4) , 1339-1344
Can Engagement Aid in Design and Accrual on Clinical Trials? Observations from Comparative Study of Proton and Photon Therapy in Prostate Cancer: A Prospective Comparison of Outcomes with Proton and Photon Radiation in Prostate Cancer
- 29 July 2026
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 126 (4) , 1339-1344
Can Engagement Aid in Design and Accrual on Clinical Trials? Observations from Comparative Study of Proton and Photon Therapy in Prostate Cancer: A Prospective Comparison of Outcomes with Proton and Photon Radiation in Prostate Cancer
- 19 July 2025
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 123 (5) , 1277-1284
Association Between Brain Substructure Dose and Scholastic Performance in Pediatric Brain Tumor Survivors Who Received Radiation Therapy
- 19 July 2025
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 123 (5) , 1277-1284
Association Between Brain Substructure Dose and Scholastic Performance in Pediatric Brain Tumor Survivors Who Received Radiation Therapy
- 14 July 2021
- Published by Springer Nature in Cancer Causes & Control
- Vol. 32 (11) , 1269-1278
Lower disease control rates and survival outcomes among Blacks with pharyngeal squamous cell carcinomas compared with Whites: a retrospective analysis at the University of Florida
Disparate clinical outcomes for pharyngeal squamous cell carcinoma (PSCC) of the oropharynx (OPSCC) and hypopharynx (HPSCC) have been observed in Black compared with White patients. Higher tobacco and alcohol use has been associated with decreased survival in Black patients with PSCC. Higher human papilloma virus (HPV) infection rates, associated with specific subsites of the oropharynx, are linked to improved overall survival (OS). Using an institutional cohort of Black and White patients with PSCC, we performed a retrospective analysis using multiple disease endpoints including local control (LC), local–regional control (LRC), freedom from distant metastases (DMFS), OS, cause-specific survival (CSS), and recorded tobacco and alcohol use. 1419 patients [Black (n = 111) and White (n = 1,308)] treated for PSCC from 1973 to 2013 were evaluated. PSCC 5- and 10-year LC, LRC, and DMFS and CSS rates were lower for Blacks. Notably, Black patients with OPSCC had higher stage cancers, higher percentage of soft palate tumors, and lower percentage of base of tongue cancers, were more likely to receive radiotherapy, and had higher tobacco and alcohol use. OS was significantly lower in Black patients at both anatomic sites, with the greatest difference observed for OPSCC. Multivariate analysis showed race and tobacco independently predicted DMFS, OS, and CSS; however, tobacco use had a greater impact on DMFS (HR 2.5, p = 0.021) than race (HR 1.9, p = 0.027). Overall, we propose that the higher burden of tobacco use along with a lower rate of tumors arising from traditional HPV-related subsites were important contributors to disparate disease outcomes seen in our Black patients.
- 14 July 2021
- Published by Springer Nature in Cancer Causes & Control
- Vol. 32 (11) , 1269-1278
Lower disease control rates and survival outcomes among Blacks with pharyngeal squamous cell carcinomas compared with Whites: a retrospective analysis at the University of Florida
Disparate clinical outcomes for pharyngeal squamous cell carcinoma (PSCC) of the oropharynx (OPSCC) and hypopharynx (HPSCC) have been observed in Black compared with White patients. Higher tobacco and alcohol use has been associated with decreased survival in Black patients with PSCC. Higher human papilloma virus (HPV) infection rates, associated with specific subsites of the oropharynx, are linked to improved overall survival (OS). Using an institutional cohort of Black and White patients with PSCC, we performed a retrospective analysis using multiple disease endpoints including local control (LC), local–regional control (LRC), freedom from distant metastases (DMFS), OS, cause-specific survival (CSS), and recorded tobacco and alcohol use. 1419 patients [Black (n = 111) and White (n = 1,308)] treated for PSCC from 1973 to 2013 were evaluated. PSCC 5- and 10-year LC, LRC, and DMFS and CSS rates were lower for Blacks. Notably, Black patients with OPSCC had higher stage cancers, higher percentage of soft palate tumors, and lower percentage of base of tongue cancers, were more likely to receive radiotherapy, and had higher tobacco and alcohol use. OS was significantly lower in Black patients at both anatomic sites, with the greatest difference observed for OPSCC. Multivariate analysis showed race and tobacco independently predicted DMFS, OS, and CSS; however, tobacco use had a greater impact on DMFS (HR 2.5, p = 0.021) than race (HR 1.9, p = 0.027). Overall, we propose that the higher burden of tobacco use along with a lower rate of tumors arising from traditional HPV-related subsites were important contributors to disparate disease outcomes seen in our Black patients.
- Open Access
- 21 September 2015
- Published by Springer Nature in Radiation Oncology
- Vol. 10 (1) , 199
Efficacy of elective nodal irradiation in skin squamous cell carcinoma of the face, ears, and scalp
In patients at high risk for regional node metastasis from squamous cell carcinoma (SCC) of the skin of the face, ear, or scalp, radiotherapy to the regional nodes is an alternative to parotid or neck surgery. Data on the efficacy of elective nodal radiotherapy in this setting are scarce such that there is no publication specifically addressing the subject. The purpose of our study is to fill this void in the skin cancer literature. This is a single-institution study of outcomes following elective nodal radiotherapy in 71 consecutively treated adults with SCC of the face, ears, or scalp. Primary site stage distribution per the American Joint Committee on Cancer, 7th Edition, was as follows: T1, 15 %; T2, 34 %; T3, 1 %; and T4, 50 %. Other disease characteristics included the following: clinical perineural invasion, 13 %; pathological perineural invasion, 78 %; recurrent disease, 32 %; and positive or close margin, 67 %. The median radiation dose to the first- and second-echelon nodal area was 50 Gy. Acute and late toxicity were graded per the Common Terminology Criteria for Adverse Events, version 4.0. Regional control was assessed using the Kaplan-Meier product limit method. Median followup was 4.5 years for all patients. The actuarial regional control rate at 5 years was 96 %. There were no (0 %) grade 3 or higher complications from elective nodal irradiation. Elective nodal irradiation in patients with high-risk SCC of the face, ears and scalp is safe and effective.
- 21 September 2015
- Published by Springer Nature in Radiation Oncology
- Vol. 10 (1) , 199
Open AccessEfficacy of elective nodal irradiation in skin squamous cell carcinoma of the face, ears, and scalp
In patients at high risk for regional node metastasis from squamous cell carcinoma (SCC) of the skin of the face, ear, or scalp, radiotherapy to the regional nodes is an alternative to parotid or neck surgery. Data on the efficacy of elective nodal radiotherapy in this setting are scarce such that there is no publication specifically addressing the subject. The purpose of our study is to fill this void in the skin cancer literature. This is a single-institution study of outcomes following elective nodal radiotherapy in 71 consecutively treated adults with SCC of the face, ears, or scalp. Primary site stage distribution per the American Joint Committee on Cancer, 7th Edition, was as follows: T1, 15 %; T2, 34 %; T3, 1 %; and T4, 50 %. Other disease characteristics included the following: clinical perineural invasion, 13 %; pathological perineural invasion, 78 %; recurrent disease, 32 %; and positive or close margin, 67 %. The median radiation dose to the first- and second-echelon nodal area was 50 Gy. Acute and late toxicity were graded per the Common Terminology Criteria for Adverse Events, version 4.0. Regional control was assessed using the Kaplan-Meier product limit method. Median followup was 4.5 years for all patients. The actuarial regional control rate at 5 years was 96 %. There were no (0 %) grade 3 or higher complications from elective nodal irradiation. Elective nodal irradiation in patients with high-risk SCC of the face, ears and scalp is safe and effective.